Astrocytoma, IDH-Mutant, Grade 2 — Trials

Astrocytoma, IDH-Mutant, Grade 2 — Trials · CancerIndex

Clinical trials

Registered studies

8 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

clinicaltrialsPublishedShowing 1–1 of 1 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05303519	SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)(SIGMA)	recruiting	Phase 3	365	Nuvation Bio Inc.INDUSTRY	3	Aug 28, 2026	clinicaltrials

Data updated 23 days agoSource updated Aug 28, 2026source: clinicaltrials